ATHENTIA NEXT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ATHENTIA NEXT (ATHENTIA NEXT).
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
| Metabolism | Levonorgestrel is metabolized by CYP3A4; ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation. |
| Excretion | Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%. |
| Half-life | Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing. |
| Protein binding | ~95% bound primarily to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 85-95%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes. |
| Duration of Action | 12-24 hours depending on dose and indication; clinical effect persists for the dosing interval. |
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
| Dosage form | TABLET |
| Renal impairment | No data available. Dose adjustment recommendations cannot be provided. |
| Liver impairment | No data available. Dose adjustment recommendations cannot be provided. |
| Pediatric use | No data available. Pediatric dosing not established. |
| Geriatric use | No data available. Geriatric-specific considerations not established. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ATHENTIA NEXT (ATHENTIA NEXT).
| Breastfeeding | Contraindicated during breastfeeding due to potential for serious adverse reactions in nursing infants. M/P ratio not determined; drug is excreted in human milk in unknown amounts. Discontinue drug or breastfeeding. |
| Teratogenic Risk | Pregnancy Category D. First trimester: Increased risk of spontaneous abortion and major congenital malformations, including cardiovascular and central nervous system defects. Second and third trimesters: Potential for oligohydramnios, fetal renal impairment, and premature closure of ductus arteriosus. Avoid use in pregnant women unless benefit outweighs risk. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events; contraindicated in women over 35 who smoke.
| Serious Effects |
Current or history of thromboembolic disorders, cerebrovascular disease, known or suspected pregnancy, liver disease, undiagnosed abnormal uterine bleeding, hypersensitivity to components.
| Precautions | Increased risk of thromboembolic events, myocardial infarction, and stroke, especially in smokers over 35. Caution in hypertension, diabetes, hyperlipidemia, and migraine with aura. |
| Food/Dietary | Grapefruit juice should be avoided as it inhibits CYP3A4, potentially increasing netupitant levels. There are no other known food restrictions. Take with or without food. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes; fetal ultrasound for amniotic fluid volume, fetal growth, and ductus arteriosus patency; nonstress test or biophysical profile as indicated. |
| Fertility Effects | May impair female fertility by disrupting ovulation and luteal function. Animal studies show reduced fertility rates. Reversible upon discontinuation. |
| Clinical Pearls | ATHENTIA NEXT is a combination of netupitant and palonosetron for prevention of chemotherapy-induced nausea and vomiting (CINV). Netupitant is a long-acting NK1 receptor antagonist; palonosetron is a 5-HT3 receptor antagonist with a longer half-life than other 5-HT3 antagonists. Administer as a single oral dose 1 hour prior to chemotherapy. Do not use with strong CYP3A4 inducers or inhibitors without dose adjustment. Monitor for serotonin syndrome when combined with other serotonergic drugs. The capsule should be swallowed whole with liquid. |
| Patient Advice | Take one capsule about 1 hour before your chemotherapy session. · Swallow the capsule whole with water; do not crush or chew. · You may experience headache, constipation, or mild tiredness; notify your doctor if severe. · Avoid drinking grapefruit juice during treatment as it may affect how the drug works. · Report any signs of allergic reaction (rash, itching, swelling, trouble breathing) immediately. · This medication prevents nausea and vomiting; it will not treat symptoms once they have started. |